05 February 2026
05 February 2026
Despite being saddled with tariffs and lagging behind China and the US, European sites offer biopharma suppliers a chance to diversify.
Lilly anticipates revenue of between $80bn and $83bn in 2026 – a year that could see orforglipron enter the US market.
The company is hoping that its accelerated R&D strategy and new launches will help offset the impact of upcoming patent expiries within its portfolio.
The closing of this transaction is expected during the second half of 2026.
Everest Medicines expects the partnership to complement its renal pipeline and broaden its nephrology product range.
Novo blamed US pricing erosion and patent expiries in several markets for the bleak 2026 outlook.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
